CATAPRES
LOE ApproachingNDAORALTABLETPriority Review
Approved
Sep 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
CATAPRES by Boehringer Ingelheim is system structure and components catapres‑tts is a multi-layered film, 0. Approved for the treatment of hypertension. First approved in 1974.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAPRES (clonidine) is a small-molecule antihypertensive agent approved in 1974 for the treatment of hypertension. It works as a central alpha-2 adrenergic agonist that reduces sympathetic nervous system outflow, thereby lowering blood pressure. Available as an oral tablet, CATAPRES remains a foundational therapy in hypertension management despite its age.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating defending-market operations rather than growth expansion opportunities.
Mechanism of Action
System Structure and Components Catapres‑TTS is a multi-layered film, 0.2 mm thick, containing clonidine as the active agent. The system areas are 4.33 cm(Catapres‑TTS‑1), 8.67 cm (Catapres‑TTS‑2) and 13 cm (Catapres‑TTS‑3) and the amount of drug released is directly proportional to the area (see…
Indications (1)
Worked on CATAPRES at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.